Limits...
Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).

Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C - Med. Sci. Monit. (2011)

Bottom Line: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications.After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Dresden University of Technology, Dresden, Germany. openphw@googlemail.com

ABSTRACT

Background: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis.

Material/methods: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading.

Results: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).

Conclusions: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

Show MeSH

Related in: MedlinePlus

Comparison of tumour response rates according to EASL: OR, objective response, DC disease control rate ([%] of patients).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539521&req=5

f6-medscimonit-17-4-cr189: Comparison of tumour response rates according to EASL: OR, objective response, DC disease control rate ([%] of patients).

Mentions: After an average of 8 months, complete remission was achieved in 13.6% vs. 0% of patients, partial remission in 9.1% vs. 22.7% of patients and stable disease in 68.2% vs. 45.5 of patients in the DEB-TACE and cTACE arms respectively. Progression of the HCC was seen in 9.1% vs. 31.8% of patients (Figure 5). This results in an objective response to therapy (OR; complete remission + partial remission) of 22.7% vs. 22.7% (DEB-TACE vs. cTACE); this difference is not significant. Disease control (DC; objective response + stable disease) was achieved in 90.9% and 68.2% respectively (Figure 6). While there were no differences with regard to OR, there was a trend to better results in the DEB-TACE group on average with regard to DC (p=0.066).


Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).

Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C - Med. Sci. Monit. (2011)

Comparison of tumour response rates according to EASL: OR, objective response, DC disease control rate ([%] of patients).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539521&req=5

f6-medscimonit-17-4-cr189: Comparison of tumour response rates according to EASL: OR, objective response, DC disease control rate ([%] of patients).
Mentions: After an average of 8 months, complete remission was achieved in 13.6% vs. 0% of patients, partial remission in 9.1% vs. 22.7% of patients and stable disease in 68.2% vs. 45.5 of patients in the DEB-TACE and cTACE arms respectively. Progression of the HCC was seen in 9.1% vs. 31.8% of patients (Figure 5). This results in an objective response to therapy (OR; complete remission + partial remission) of 22.7% vs. 22.7% (DEB-TACE vs. cTACE); this difference is not significant. Disease control (DC; objective response + stable disease) was achieved in 90.9% and 68.2% respectively (Figure 6). While there were no differences with regard to OR, there was a trend to better results in the DEB-TACE group on average with regard to DC (p=0.066).

Bottom Line: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications.After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Dresden University of Technology, Dresden, Germany. openphw@googlemail.com

ABSTRACT

Background: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis.

Material/methods: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading.

Results: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).

Conclusions: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

Show MeSH
Related in: MedlinePlus